Osteoclast-derived apoptotic bodies inhibit naive CD8+ T cell activation via Siglec15, promoting breast cancer secondary metastasis

Coleman, 2020, Bone metastases, Nat. Rev. Dis. Prim., 6, 83, 10.1038/s41572-020-00216-3 Zhang, 2021, The bone microenvironment invigorates metastatic seeds for further dissemination, Cell, 184, 2471, 10.1016/j.cell.2021.03.011 Hofbauer, 2014, Endocrine aspects of bone metastases, Lancet Diabetes Endocrinol., 2, 500, 10.1016/S2213-8587(13)70203-1 Friedl, 2021, Prognosis of Patients With Early Breast Cancer Receiving 5 Years vs 2 Years of Adjuvant Bisphosphonate Treatment: A Phase 3 Randomized Clinical Trial, JAMA Oncol., 7, 1149, 10.1001/jamaoncol.2021.1854 Raggatt, 2010, Cellular and molecular mechanisms of bone remodeling, J. Biol. Chem., 285, 25103, 10.1074/jbc.R109.041087 Ma, 2019, Mature osteoclast-derived apoptotic bodies promote osteogenic differentiation via RANKL-mediated reverse signaling, J. Biol. Chem., 294, 11240, 10.1074/jbc.RA119.007625 Ma, 2020, Osteoclast-derived apoptotic bodies show extended biological effects of parental cell in promoting bone defect healing, Theranostics, 10, 6825, 10.7150/thno.45170 Ma, 2021, Osteoclast-derived apoptotic bodies couple bone resorption and formation in bone remodeling, Bone Res, 9, 5, 10.1038/s41413-020-00121-1 Raskov, 2021, Cytotoxic CD8(+) T cells in cancer and cancer immunotherapy, Br. J. Cancer, 124, 359, 10.1038/s41416-020-01048-4 Li, 2021, CD8(+) T cell immunity blocks the metastasis of carcinogen-exposed breast cancer, Sci. Adv., 7 Ali, 2014, Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients, Ann. Oncol., 25, 1536, 10.1093/annonc/mdu191 Vihervuori, 2019, Tumor-infiltrating lymphocytes and CD8(+) T cells predict survival of triple-negative breast cancer, J. Cancer Res. Clin. Oncol., 145, 3105, 10.1007/s00432-019-03036-5 Ibrahim, 2014, The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis, Breast Cancer Res. Treat., 148, 467, 10.1007/s10549-014-3185-2 Nanda, 2016, Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study, J. Clin. Oncol., 34, 2460, 10.1200/JCO.2015.64.8931 Wang, 2019, Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy, Nat. Med., 25, 656, 10.1038/s41591-019-0374-x Dou, 2022, Sialylation of TLR2 initiates osteoclast fusion, Bone Res, 10, 24, 10.1038/s41413-022-00186-0 Watson, 1992, Genetic analysis of MRL-lpr mice: relationship of the Fas apoptosis gene to disease manifestations and renal disease-modifying loci, J. Exp. Med., 176, 1645, 10.1084/jem.176.6.1645 Chang, 2017, Identification of Siglec Ligands Using a Proximity Labeling Method, J. Proteome Res., 16, 3929, 10.1021/acs.jproteome.7b00625 Geng, 2010, When Toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced CD8 T-cell effector function, Blood, 116, 3494, 10.1182/blood-2010-02-268169 Komai-Koma, 2004, TLR2 is expressed on activated T cells as a costimulatory receptor, Proc. Natl. Acad. Sci. USA, 101, 3029, 10.1073/pnas.0400171101 Smith, 2021, The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans, Nat. Rev. Drug Discov., 20, 217, 10.1038/s41573-020-00093-1 Rogers, 2000, Cellular and molecular mechanisms of action of bisphosphonates, Cancer, 88, 2961, 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L Chen, 2010, Breast cancer metastasis to the bone: mechanisms of bone loss, Breast Cancer Res., 12, 215, 10.1186/bcr2781 Onishi, 2010, Future directions of bone-targeted therapy for metastatic breast cancer, Nat. Rev. Clin. Oncol., 7, 641, 10.1038/nrclinonc.2010.134 Maurizi, 2018, The Osteoclast in Bone Metastasis: Player and Target, Cancers, 10, 10.3390/cancers10070218 Le Pape, 2016, The role of osteoclasts in breast cancer bone metastasis, J Bone Oncol, 5, 93, 10.1016/j.jbo.2016.02.008 Gnant, 2019, Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial, Lancet Oncol., 20, 339, 10.1016/S1470-2045(18)30862-3 Early Breast Cancer Trialists' Collaborative, 2015, Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials, Lancet, 386, 1353, 10.1016/S0140-6736(15)60908-4 Drake, 2008, Bisphosphonates: mechanism of action and role in clinical practice, Mayo Clin. Proc., 83, 1032, 10.4065/83.9.1032 Russell, 2007, Bisphosphonates: mode of action and pharmacology, Pediatrics, 119, S150, 10.1542/peds.2006-2023H Sun, 2021, Siglec-15 as an Emerging Target for Next-generation Cancer Immunotherapy, Clin. Cancer Res., 27, 680, 10.1158/1078-0432.CCR-19-2925 Jiang, 2022, The intriguing roles of Siglec family members in the tumor microenvironment, Biomark Res, 10, 22, 10.1186/s40364-022-00369-1 Angata, 2020, Siglec-15: a potential regulator of osteoporosis, cancer, and infectious diseases, J. Biomed. Sci., 27, 10, 10.1186/s12929-019-0610-1 Ren, 2019, Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle, Cancer Biol Med, 16, 205, 10.20892/j.issn.2095-3941.2018.0141 Salerno, 2019, Costimulation through TLR2 Drives Polyfunctional CD8(+) T Cell Responses, J. Immunol., 202, 714, 10.4049/jimmunol.1801026 Mills, 2011, TLR-dependent T cell activation in autoimmunity, Nat. Rev. Immunol., 11, 807, 10.1038/nri3095 Wang, 2018, Adjuvant effect of the novel TLR1/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice, Proc. Natl. Acad. Sci. USA, 115, E8698 Hennessy, 2010, Targeting Toll-like receptors: emerging therapeutics?, Nat. Rev. Drug Discov., 9, 293, 10.1038/nrd3203 Pearce, 2016, Sialic acids in cancer biology and immunity, Glycobiology, 26, 111, 10.1093/glycob/cwv097 Dobie, 2021, Insights into the role of sialylation in cancer progression and metastasis, Br. J. Cancer, 124, 76, 10.1038/s41416-020-01126-7 Pietrobono, 2021, Aberrant Sialylation in Cancer: Biomarker and Potential Target for Therapeutic Intervention?, Cancers, 13, 10.3390/cancers13092014 Kolbl, 2015, The Role of Glycosylation in Breast Cancer Metastasis and Cancer Control, Front. Oncol., 5, 219, 10.3389/fonc.2015.00219 Ozturk, 2011, Salivary total sialic acid levels increase in breast cancer patients: a preliminary study, Med. Chem., 7, 443, 10.2174/157340611796799230 Hogan-Ryan, 1980, Serum sialic acid and CEA concentrations in human breast cancer, Br. J. Cancer, 41, 587, 10.1038/bjc.1980.101 Scott, 2019, Glycosylation and its implications in breast cancer, Expert Rev. Proteomics, 16, 665, 10.1080/14789450.2019.1645604 Lairson, 2008, Glycosyltransferases: structures, functions, and mechanisms, Annu. Rev. Biochem., 77, 521, 10.1146/annurev.biochem.76.061005.092322 Zhou, 2020, Sialidase NEU1 suppresses progression of human bladder cancer cells by inhibiting fibronectin-integrin alpha5beta1 interaction and Akt signaling pathway, Cell Commun. Signal., 18, 44, 10.1186/s12964-019-0500-x Muhsin-Sharafaldine, 2018, Tumor-Derived Apoptotic Vesicles: With Death They Do Part, Front. Immunol., 9, 957, 10.3389/fimmu.2018.00957 Lynch, 2017, Extracellular Vesicles Arising from Apoptotic Cells in Tumors: Roles in Cancer Pathogenesis and Potential Clinical Applications, Front. Immunol., 8, 1174, 10.3389/fimmu.2017.01174 Pavlyukov, 2018, Apoptotic Cell-Derived Extracellular Vesicles Promote Malignancy of Glioblastoma Via Intercellular Transfer of Splicing Factors, Cancer Cell, 34, 119, 10.1016/j.ccell.2018.05.012